Literature DB >> 32159783

The impact of empagliflozin on kidney injury molecule-1: a subanalysis of the Effects of Empagliflozin on Cardiac Structure, Function, and Circulating Biomarkers in Patients with Type 2 Diabetes CardioLink-6 trial.

Erika Opingari1,2, Subodh Verma1,2,3,4, Kim A Connelly2,5,6,7, Cyril David Mazer7,8,9, Hwee Teoh1,10, Adrian Quan1, Fei Zuo11, Yi Pan1, Deepak L Bhatt12, Bernard Zinman6,13, Lawrence A Leiter6,10,14, Andrew T Yan5,6, David Z I Cherney2,6,7,15, Richard E Gilbert2,6,10.   

Abstract

Entities:  

Year:  2020        PMID： 32159783     DOI： 10.1093/ndt/gfz294

Source DB:  PubMed          Journal:  Nephrol Dial Transplant        ISSN： 0931-0509            Impact factor:   5.992


× No keyword cloud information.
  5 in total

Review 1.  SGLT2 Inhibition in Type 1 Diabetes with Diabetic Kidney Disease: Potential Cardiorenal Benefits Can Outweigh Preventable Risk of Diabetic Ketoacidosis.

Authors:  Hongyan Liu; Vikas S Sridhar; Bruce A Perkins; Julio Rosenstock; David Z I Cherney
Journal:  Curr Diab Rep       Date:  2022-05-28       Impact factor: 4.810

Review 2.  Effects of SGLT2 Inhibitors on Kidney and Cardiovascular Function.

Authors:  Volker Vallon; Subodh Verma
Journal:  Annu Rev Physiol       Date:  2020-11-16       Impact factor: 19.318

Review 3.  Effects of Sodium-Glucose Cotransporter 2 Inhibitors on Water and Sodium Metabolism.

Authors:  Jun Tang; Lifang Ye; Qiqi Yan; Xin Zhang; Lihong Wang
Journal:  Front Pharmacol       Date:  2022-02-23       Impact factor: 5.810

4.  Biomarkers of Kidney Tubule Disease and Risk of End-Stage Kidney Disease in Persons With Diabetes and CKD.

Authors:  Jonathan G Amatruda; Ronit Katz; Mark J Sarnak; Orlando M Gutierrez; Jason H Greenberg; Mary Cushman; Sushrut Waikar; Chirag R Parikh; Jeffrey R Schelling; Manasi P Jogalekar; Joseph V Bonventre; Ramachandran S Vasan; Paul L Kimmel; Michael G Shlipak; Joachim H Ix
Journal:  Kidney Int Rep       Date:  2022-04-05

5.  Renal and Cardiovascular Effects of SGLT2 Inhibition in Combination With Loop Diuretics in Patients With Type 2 Diabetes and Chronic Heart Failure: The RECEDE-CHF Trial.

Authors:  Natalie A Mordi; Ify R Mordi; Jagdeep S Singh; Rory J McCrimmon; Allan D Struthers; Chim C Lang
Journal:  Circulation       Date:  2020-08-29       Impact factor: 29.690
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.